2. Gene
  3. Akt3 - AKT serine/threonine kinase 3 Gene

Akt3 - AKT serine/threonine kinase 3 Gene

  • Gene
  • Protein
  • Agent
  • Ortholog
Rattus norvegicus

Also known as Pkbg

Gene ID: 29414 | Gene type: protein coding

About Akt3

Primary_assembly 13: 88,946,091-89,225,708 reverse strand.mRatBN7.2:CM026986.1

This gene has 2 transcripts (splice variants), 203 orthologues, 5 paralogues and is associated with 22 phenotypes. Biased expression in Brain (RPKM 538.7), Thymus (RPKM 188.1) and 8 other tissues.

Summary

Enables ATP binding activity; protein kinase C binding activity; and protein serine/threonine kinase activity. Involved in protein phosphorylation. Acts upstream of or within cellular response to Insulin stimulus and positive regulation of sodium ion transport. Predicted to be located in cytosol and nucleoplasm. Human ortholog(s) of this gene implicated in colon cancer; glioblastoma; prostate adenocarcinoma; prostate cancer; and renal cell carcinoma. Orthologous to human Akt3 (Akt serine/threonine kinase 3). [provided by Alliance of Genome Resources, Apr 2022]

Akt3 Products(1)

mRNA Protein Name
NM_031575.2 NP_113763.2 RAC-gamma serine/threonine-protein kinase

Akt3 Protein Structure

PH_PKB

PH_PKB: cd01241 (3 - 132)

PKc_like

PKc_like: cl21453 (174 - 441)

  • 0
  • 100
  • 200
  • 300
  • 400
  • 504 a.a.
Protein Preferred Names Protein Names

RAC-gamma serine/threonine-protein kinase

AKT3 kinase

PKB gamma

RAC-PK-gamma

protein kinase Akt-3

protein kinase B, gamma

thymoma viral proto-oncogene 3

v-akt murine thymoma viral oncogene 3

v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma)

Related Agents

Clinical Phase
Bioactive Molecules (17)
Cat. No. Product Name Effect
Purity Phase
HY-15186 Ipatasertib Inhibitor 99.88% Phase 4
HY-15186A Ipatasertib dihydrochloride Inhibitor 99.27% Phase 4
HY-15431 Capivasertib Inhibitor 99.95% Phase 3
HY-10358 MK-2206 dihydrochloride Inhibitor 99.99% Phase 2
HY-19719 Miransertib Inhibitor 99.32% Phase 2
HY-15727 Afuresertib Inhibitor 99.54% Phase 2
HY-15965 Uprosertib Inhibitor 99.74% Phase 2
HY-19934A Pifusertib hydrochloride Inhibitor 98.96% Phase 2
HY-15727A Afuresertib hydrochloride Inhibitor 99.03% Phase 2
HY-19719A Miransertib hydrochloride Inhibitor 99.74% Phase 2
HY-19934 Pifusertib Inhibitor / Phase 2
HY-108232 MK-2206 Inhibitor / Phase 2
HY-15965A Uprosertib hydrochloride Inhibitor / Phase 2
HY-10249 GSK-690693 Inhibitor 98.46% Phase 1
HY-100018 BAY1125976 Inhibitor 99.74% Phase 1
HY-16071 AT13148 Inhibitor 99.21% Phase 1
HY-137458 Vevorisertib Inhibitor / Phase 1
Pre-clinical Phase
Bioactive Molecules (20)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-10355 AKT inhibitor VIII Inhibitor 98.97% Unkown
HY-10425 A-443654 Inhibitor 98.50% Unkown
HY-137458A Vevorisertib trihydrochloride Inhibitor 99.13% Unkown
HY-12059 AT7867 Inhibitor 99.88% Unkown
HY-133120 INY-03-041 Inhibitor 98.64% Unkown
HY-151504 ALM301 Inhibitor 99.33% Unkown
HY-12059A AT7867 dihydrochloride Inhibitor 99.75% Unkown
HY-145282 MS170 Inhibitor 99.72% Unkown
HY-126257 AKT-IN-3 Inhibitor 99.29% Unkown
HY-151613 MS15 Inhibitor / Unkown
HY-133120A INY-03-041 trihydrochloride Inhibitor 99.27% Unkown
HY-145281 MS98 Inhibitor / Unkown
HY-132302A Hu7691 free base Inhibitor / Unkown
HY-10357 MK-2206 free base Inhibitor / Unkown
HY-147935 NTQ1062 Inhibitor / Unkown
HY-132302 Hu7691 Inhibitor / Unkown
HY-129119 Akt1/Akt2-IN-2 Inhibitor / Unkown
HY-147937 AKT-IN-13 Inhibitor / Unkown
HY-143611 AKT-IN-8 Inhibitor / Unkown
HY-16032 Akt1-IN-2 Inhibitor / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens Akt3 NCBI NCBI:10000
Mus musculus Akt3 NCBI NCBI:23797